[Oral anticoagulation in chronic kidney disease with atrial fibrillation]. / Anticoagulación oral en la enfermedad renal crónica con fibrilación auricular.
Med Clin (Barc)
; 144(10): 452-6, 2015 May 21.
Article
en Es
| MEDLINE
| ID: mdl-24889748
ABSTRACT
Atrial fibrillation is a common finding in patients with chronic kidney disease (CKD), which increases markedly the embolism risk. The CHADS2 and HAS-BLED scales, used in the general population to assess the risk/benefit of oral anticoagulation (OAC), underestimate respectively the risk of embolism and haemorrhage in CKD, making it difficult to decide whether to use OAC or not. Based on the available evidence, it seems indicated to use OAC in stage 3 CKD, while it is controversial in advanced stages. New OAC such as dabigatran and rivaroxaban have been approved in stage 3 CKD but their role is still somewhat uncertain.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Fibrilación Atrial
/
Accidente Cerebrovascular
/
Embolia
/
Insuficiencia Renal Crónica
/
Hemorragia
/
Anticoagulantes
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
Es
Revista:
Med Clin (Barc)
Año:
2015
Tipo del documento:
Article